Lundbeck-exec denies AZ rumor
Bloomberg has reported that Danish drug group Lundbeck is considering striking a deal with UK group AstraZeneca. But Lundbeck’s R&D chief says that is an “over-interpretation”.
by Benjamin Werner Christensen
It caused some stir this week when Bloomberg News according to Danish news agency Ritzau reported that Lundbeck was considering entering into a partnership with UK drug company AstraZeneca. But the story has no basis in reality, explains Lundbeck’s R&D chief. The deal would supposedly be centered on AZ’s Alzheimer’s candidate AZD3293, which has completed mid-stage clinical trials.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
R&D chief: Brintellix data are highly significant
For abonnenter
VP: Lundbeck first with new Alzheimer’s drug
For abonnenter
Doctors represent hurdle for Lundbeck once again
For abonnenter
